These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 1151528

  • 1. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.
    Risdon RA, Barry M, Flynn DM.
    J Pathol; 1975 Jun; 116(2):83-95. PubMed ID: 1151528
    [Abstract] [Full Text] [Related]

  • 2. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
    Mazza P, Giua R, De Marco S, Bonetti MG, Amurri B, Masi C, Lazzari G, Rizzo C, Cervellera M, Peluso A.
    Haematologica; 1995 Jun; 80(5):398-404. PubMed ID: 8566878
    [Abstract] [Full Text] [Related]

  • 3. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.
    Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F, Ferraro D, Cuccia L, Ruffo GB, Bronte F, Di Stefano R, Almasio PL, Craxì A.
    Haematologica; 2008 Aug; 93(8):1243-6. PubMed ID: 18556410
    [Abstract] [Full Text] [Related]

  • 4. Liver iron overload and liver fibrosis in thalassemia.
    Angelucci E, Baronciani D, Lucarelli G, Giardini C, Galimberti M, Polchi P, Martinelli F, Baldassarri M, Muretto P.
    Bone Marrow Transplant; 1993 Aug; 12 Suppl 1():29-31. PubMed ID: 8374556
    [No Abstract] [Full Text] [Related]

  • 5. Hepatic siderosis, fibrosis and cirrhosis: the association with hepatocellular carcinoma in high-risk population.
    Jaskiewicz K, Banach L, Lancaster E.
    Anticancer Res; 1997 Aug; 17(5B):3897-9. PubMed ID: 9427800
    [Abstract] [Full Text] [Related]

  • 6. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
    Sheth S, Tang H, Jensen JH, Altmann K, Prakash A, Printz BF, Hordof AJ, Tosti CL, Azabagic A, Swaminathan S, Brown TR, Olivieri NF, Brittenham GM.
    Ann N Y Acad Sci; 2005 Aug; 1054():358-72. PubMed ID: 16339684
    [Abstract] [Full Text] [Related]

  • 7. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 8. Reduction of iron overload in thalassemia.
    Piomelli S, Graziano J.
    Birth Defects Orig Artic Ser; 1982 Apr; 18(7):339-46. PubMed ID: 7159742
    [No Abstract] [Full Text] [Related]

  • 9. Treatment of hepatitis C virus infection in thalassemia.
    Butensky E, Pakbaz Z, Foote D, Walters MC, Vichinsky EP, Harmatz P.
    Ann N Y Acad Sci; 2005 Apr; 1054():290-9. PubMed ID: 16339677
    [Abstract] [Full Text] [Related]

  • 10. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.
    Barry M, Flynn DM, Letsky EA, Risdon RA.
    Br Med J; 1974 Apr 06; 2(5909):16-20. PubMed ID: 4821036
    [Abstract] [Full Text] [Related]

  • 11. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R.
    Arch Intern Med; 1985 Jul 06; 145(7):1217-21. PubMed ID: 3925909
    [Abstract] [Full Text] [Related]

  • 12. [Cardiological findings, transfusional regimen, hepatic biopsy and splenectomy in 16 thalassemic patients in the post-pediatric age].
    Montaldo PL, Loddo M, Satta L, Multineddu R, Perpignano G, Pintus A, Lixi M, Carcassi U.
    Boll Soc Ital Cardiol; 1979 Jul 06; 24(1):87-91. PubMed ID: 161970
    [No Abstract] [Full Text] [Related]

  • 13. Non-invasive assessment of liver fibrosis by transient elastography in post transfusional iron overload.
    Mirault T, Lucidarme D, Turlin B, Vandevenne P, Gosset P, Ernst O, Rose C.
    Eur J Haematol; 2008 Apr 06; 80(4):337-40. PubMed ID: 18081722
    [Abstract] [Full Text] [Related]

  • 14. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.
    Porter JB, Davis BA.
    Best Pract Res Clin Haematol; 2002 Jun 06; 15(2):329-68. PubMed ID: 12401311
    [Abstract] [Full Text] [Related]

  • 15. Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT).
    Maira D, Cassinerio E, Marcon A, Mancarella M, Fraquelli M, Pedrotti P, Cappellini MD.
    Ann Hematol; 2017 Nov 06; 96(11):1931-1936. PubMed ID: 28875336
    [Abstract] [Full Text] [Related]

  • 16. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct 06; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 17. The liver in thalassaemia major: ultrastructural observations.
    Iancu TC, Neustein HB, Landing BH.
    Ciba Found Symp; 1995 Oct 06; (51):293-316. PubMed ID: 1052035
    [Abstract] [Full Text] [Related]

  • 18. Quantitative analysis and modelling of hepatic iron stores using stereology and spatial statistics.
    Ghugre NR, Gonzalez-Gomez I, Shimada H, Coates TD, Wood JC.
    J Microsc; 2010 Jun 01; 238(3):265-74. PubMed ID: 20579264
    [Abstract] [Full Text] [Related]

  • 19. Hepatic iron concentration and total body iron stores in thalassemia major.
    Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G.
    N Engl J Med; 2000 Aug 03; 343(5):327-31. PubMed ID: 10922422
    [Abstract] [Full Text] [Related]

  • 20. Pancreatic iron loading in chronically transfused sickle cell disease is lower than in thalassaemia major.
    Noetzli LJ, Coates TD, Wood JC.
    Br J Haematol; 2011 Jan 03; 152(2):229-33. PubMed ID: 21118197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.